Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 28, 2018
Vifor Pharma today announced the launch of an inaugural Swiss Franc straight bond in the amount of CHF 465 million in the Swiss domestic market. The bond carries a 0.75% fixed coupon with a tenor...
-
Aug 23, 2018- The only treatment for hemophilia B FDA approved for up to 14-day dosing is now available in larger, 3500 IU vial size - IDELVION is now offered in 5 convenient vial sizes to fit any dosing regimen: 250, 500, 1000, 2000 and 3500 IU - New vial option delivers on CSL Behring’s promise to enhance current treatments and provide more alternatives to patients
23 Aug 2018 KING OF PRUSSIA, Pa. – 23 August 2018 – Global biotherapeutics leader CSL Behring today announced that IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein...
-
Aug 8, 2018
Strong financial performance in H1 2018 Three medium-term strategic growth drivers fully on track #Strategic in-licensing deal concluded with Cara Therapeutics Inc Net sales and EBITDA guidance...
-
Jul 20, 2018• Presentations include new analysis from the PATH trial, the largest clinical trial in CIDP
• CSL Behring is now the only company to offer a portfolio of biologics to address the unique needs of CIDP patients in the US – Hizentra®, the first and only subcutaneous immunoglobulin...
-
Jul 5, 2018- CSL Behring hosts symposium featuring patient perspective on subcutaneous immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment
- CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of CIDP patients – Hizentra®, the first and only subcutaneous immunoglobulin option for CIDP patients...